Evidence map›Paper›PMID 39741163›Full record

ArticleScientific reports2024

Evolution of SARS-CoV-2 spike trimers towards optimized heparan sulfate cross-linking and inter-chain mobility.

Jurij Froese, Marco Mandalari, Monica Civera, Stefano Elli, Isabel Pagani, Elisa Vicenzi, Itzel Garcia-Monge, Daniele Di Iorio, Saskia Frank, Antonella Bisio and 7 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jurij FroeseInstitute of Physiological Chemistry and Pathobiochemistry, University of Münster, Waldeyerstrasse 15, D-48149, Münster, Germany.
Marco MandalariIstituto di Ricerche Chimiche e Biochimiche "G. Ronzoni", Via Giuseppe Colombo 81, Milano, 20133, Italy.
Monica CiveraDipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, Milano, 20133, Italy.
Stefano ElliIstituto di Ricerche Chimiche e Biochimiche "G. Ronzoni", Via Giuseppe Colombo 81, Milano, 20133, Italy.
Isabel PaganiViral Pathogenesis and Biosafety Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Elisa VicenziViral Pathogenesis and Biosafety Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Itzel Garcia-MongeSchool of Biomedical Sciences, Faculty of Biological Sciences, School of Physics and Astronomy, Faculty of Engineering and Physical Sciences, Astbury Centre for Structural Molecular Biology, and Bragg Centre for Materials Research, University of Leeds, Leeds, LS2 9JT, UK.
Daniele Di IorioInstitute of Physiological Chemistry and Pathobiochemistry, University of Münster, Waldeyerstrasse 15, D-48149, Münster, Germany.
Saskia FrankInstitute of Physiological Chemistry and Pathobiochemistry, University of Münster, Waldeyerstrasse 15, D-48149, Münster, Germany.
Antonella BisioIstituto di Ricerche Chimiche e Biochimiche "G. Ronzoni", Via Giuseppe Colombo 81, Milano, 20133, Italy.
Dominik LenhartBene PharmaChem GmbH and Co.KG, Geretsried, Germany.
Rudolf GruberBene PharmaChem GmbH and Co.KG, Geretsried, Germany.
Edwin A YatesDepartment of Biochemistry, Systems and Cell Biology, Institute of Molecular, Integrative and Systems Biology, University of Liverpool, Liverpool, L69 7ZB, UK.
Ralf P RichterSchool of Biomedical Sciences, Faculty of Biological Sciences, School of Physics and Astronomy, Faculty of Engineering and Physical Sciences, Astbury Centre for Structural Molecular Biology, and Bragg Centre for Materials Research, University of Leeds, Leeds, LS2 9JT, UK.
Marco GuerriniIstituto di Ricerche Chimiche e Biochimiche "G. Ronzoni", Via Giuseppe Colombo 81, Milano, 20133, Italy.
Seraphine V WegnerInstitute of Physiological Chemistry and Pathobiochemistry, University of Münster, Waldeyerstrasse 15, D-48149, Münster, Germany.
Kay GrobeInstitute of Physiological Chemistry and Pathobiochemistry, University of Münster, Waldeyerstrasse 15, D-48149, Münster, Germany. kgrobe@uni-muenster.de.ORCID 0000-0002-8385-5877

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The heparan sulfate (HS)-rich extracellular matrix (ECM) serves as an initial interaction site for the homotrimeric spike (S) protein of SARS-CoV-2 to facilitate subsequent docking to angiotensin-converting enzyme 2 (ACE2) receptors and cellular infection. More recent variants, notably Omicron, have evolved by swapping several amino acids to positively charged residues to enhance the interaction of the S-protein trimer with the negatively charged HS. However, these enhanced interactions may reduce Omicron's ability to move through the HS-rich ECM to effectively find ACE2 receptors and infect cells, raising the question of how to mechanistically explain HS-associated viral movement. In this work, we show that Omicron S proteins have evolved to balance HS interaction stability and dynamics, resulting in enhanced mobility on an HS-functionalized artificial matrix. This property is achieved by the ability of Omicron S-proteins to cross-link at least two HS chains, allowing direct S-protein switching between chains as a prerequisite for cell surface mobility. Optimized HS interactions can be targeted pharmaceutically, as an HS mimetic significantly suppressed surface binding and cellular infection specifically of the Omicron variant. These findings suggest a robust way to interfere with SARS-CoV-2 Omicron infection and potentially future variants.

Indexed as

Heparan SulfateSARS-CoV-2Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2COVID-19Evolution, MolecularExtracellular MatrixHumansProtein BindingProtein MultimerizationACE2 protein, humanAngiotensin-Converting Enzyme 2Heparan SulfateSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19Heparan sulfateHeparinIntersegmental transferSARS-CoV-2S-protein

Identifiers

PMID39741163
PMCPMC11688500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.